The Europe Cardiac Marker Testing Market would witness market growth of 8.1% CAGR during the forecast period (2022-2028).
Cardiac biomarkers assist medical professionals in determining whether a heart attack (myocardial infarction), angina, heart failure, or another issue is to blame for a patient's symptoms. Increases in cardiac enzymes might potentially be a sign of myocardial ischemia or acute coronary syndrome (ACS). These conditions are treated in various ways. Making sure one receive the right care depends on a precise diagnosis.
Cardiac markers include enzymes, hormones, and proteins. They are utilized in patients for diagnosis and risk stratification in relation to chest discomfort and suspected acute coronary syndrome. They measure blood pressure and heart rate. The cardiology industry predicted to develop at the highest rate is the cardiac marker testing market, which offers excellent specificity and can aid in the detection of disorders in the early stages of presentation such as troponins.
The countries in this region have some of the best healthcare facilities in the world. According to the International Trade Administration, Germany has a very developed and powerful market for medical supplies. Carl Zeiss, Siemens, and Dragerwerk are among the companies with a long history of manufacturing high-quality medical equipment, with an emphasis on diagnostic imaging, precise medical tools, and optical technology.
The Germany market dominated the Europe Cardiac Marker Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $530.4 million by 2028.The UK market is estimated to grow a CAGR of 7.2% during (2022 - 2028). Additionally, The France market would experience a CAGR of 8.9% during (2022 - 2028).
Based on Disease, the market is segmented into Myocardial Infarction, Congestive Heart Failure, Atherosclerosis, Acute Coronary Syndrome and Ischemia. Based on End User, the market is segmented into Laboratory Testing Facilities, Point-of-Care Testing Facilities and Academic Institutions. Based on Product, the market is segmented into Reagents & Kits and Instruments. Based on Biomarker Type, the market is segmented into Troponin I & T, Creatine kinase-MB(CK-MB), Natriuretic peptide (Bnp Or Nt-Probnp), Myoglobin, High-sensitivity C-reactive protein(hs-CRP) and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Cardiac Marker Testing Market will Hit $8.1 Billion by 2028, at a CAGR of 8.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG (Siemens AG), PerkinElmer, Inc., BioMérieux S.A., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., and DiaSorin S.p.A.
By Disease
By End User
By Product
By Biomarker Type
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 